PPAR : a dagger in the heart of the metabolic syndrome
Open accessThe DOI matches its Crossref record; 97 of the 100 references it cites were found in a registry or an index.
Abstract
Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both overexpression and activation of PPARδ result in increased mitochondrial biogenesis in the absence of an increase in PGC-1α mRNA in skeletal muscle in vivo (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The finding that overexpression of PPARδ in skeletal muscle of transgenic mice does not result in an increase in PGC-1α mRNA led to the conclusion that the increase in mitochondria is mediated directly by PPARδ (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast to the finding in mouse and rat skeletal muscle that PPARδ overexpression or activation does not result in an increase in PGC-1α mRNA, a number of studies have shown that PPARδ induces an increase in PGC-1α gene transcription, with a rapid increase in PGC-1α mRNA, in myotubes (19, 50, 51).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The regulation of PGC-1α expression by PPARδ differs markedly between skeletal muscle in vivo and myotubes in culture.”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Research works printed but not linked: 1
- [77]Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.
Cited by
(1998) · PubMed · Cited by 2,737
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Transcriptional paradigms in mammalian mitochondrial biogenesis and function
Scarpulla, R. C. (2008) · Physiological Reviews · doi:10.1152/physrev.00025.2007 · Cited by 1,666
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Endocrine Disruptors: From Endocrine to Metabolic Disruption
Casals-Casas, C., & Desvergne, B. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142200 · Cited by 902
“PPARβ is ubiquitously expressed, shares partially overlapping functions with PPARα, and also plays a role in cell differentiation and survival (125, 126).”
BackgroundFluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
Kirk, K. L. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.06.007 · Cited by 900
Scott, R. A., Lagou, V., Welch, R. P., Wheeler, E., Montasser, M. E., Luan, J., Mägi, R., Strawbridge, R. J., Rehnberg, E., Gustafsson, S., et al. (2012) · Nature Genetics · doi:10.1038/ng.2385 · Cited by 828
Regulation of energy metabolism by long-chain fatty acids
Nakamura, M. T., Yudell, B. E., & Loor, J. J. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.12.001 · Cited by 818
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1
Haemmerle, G., Moustafa, T., Woelkart, G., Büttner, S., Schmidt, A., van de Weijer, T., Hesselink, M., Jaeger, D., Kienesberger, P. C., Zierler, K., et al. (2011) · Nature Medicine · doi:10.1038/nm.2439 · Cited by 761
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Alternative macrophage activation and metabolism
Odegaard, J. I., & Chawla, A. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130138 · Cited by 640
“Indeed, studies of synthetic PPARδ agonists have demonstrated great potential for use in metabolic syndrome: PPARδ activation not only promotes alternative macrophage activation and suppresses tissue inflammation (63, 64, 125) but also directly increases oxidative lipid catabolism in skeletal and cardiac muscle, adipo…”
Lopaschuk, G. D., & Jaswal, J. S. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181e74a14 · Cited by 636
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms
Straus, D. S., & Glass, C. K. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.003 · Cited by 554
High-fat diets cause insulin resistance despite an increase in muscle mitochondria
Hancock, C. R., Han, D.-H., Chen, M., Terada, S., Yasuda, T., Wright, D. C., & Holloszy, J. O. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802057105 · Cited by 538
Control of Macrophage Activation and Function by PPARs
Chawla, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.216523 · Cited by 531
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
O'Sullivan, S. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707423 · Cited by 510
“…hyperli- pidemia, atherosclerosis, metabolic syndrome and neuro- degenerative disorders (for reviews see Francis et al., 2003; Fenner and Elstner, 2005; Barish et al., 2006; Glass, 2006; Leo et al., 2007; Stienstra et al., 2007), cannabinoid actions at PPARs would provide an alternative mechanism…”
BackgroundCarazo, A., Macáková, K., Matoušová, K., Krčmová, L. K., Protti, M., & Mladěnka, P. (2021) · Nutrients · doi:10.3390/nu13051703 · Cited by 461
Mihaylova, M. M., Cheng, C.-W., Cao, A. Q., Tripathi, S., Mana, M. D., Bauer-Rowe, K. E., Abu-Remaileh, M., Clavain, L., Erdemir, A., Lewis, C. A., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.04.001 · Cited by 428
“Fasting and agonist-enforced FAO improves ISC function in aged mice Because fasting augments ISC function in young mice through a PPAR-FAO axis, we asked whether fasting or agonist-enforced FAO would also recapitulate these regenerative effects in aged ISCs (Barish et al., 2006; Beyaz et al., 2016.”
BackgroundRegulation of Angiogenesis by Oxygen and Metabolism
Fraisl, P., Mazzone, M., Schmidt, T., & Carmeliet, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.003 · Cited by 413
“Three isoforms have been described (PPAR a , PPAR b / d , and PPAR g ), each with distinct roles (Barish et al., 2006; Evans et al., 2004; Lefeb-vre et al., 2006); two inhibit angiogenesis and one promotes vessel growth.”
BackgroundJaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.015 · Cited by 400
Scarpulla, R. C. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.006 · Cited by 391
Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet
Cheng, C.-W., Biton, M., Haber, A. L., Gunduz, N., Eng, G., Gaynor, L. T., Tripathi, S., Calibasi-Kocal, G., Rickelt, S., Butty, V. L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.048 · Cited by 373
“Another possibility is that systemic and intestinal βOHB production provides a signaling circuit that couples organismal diet and metabolism to intestinal adaptation (Barish et al., 2006; Beyaz et al., 2016; Ito et al., 2012; Narkar et al., 2008).”
BackgroundPPAR-δ senses and orchestrates clearance of apoptotic cells to promote tolerance
Mukundan, L., Odegaard, J. I., Morel, C. R., Heredia, J. E., Mwangi, J. W., Ricardo-Gonzalez, R. R., Goh, Y. P. S., Eagle, A. R., Dunn, S. E., Awakuni, J. U. H., et al. (2009) · Nature Medicine · doi:10.1038/nm.2048 · Cited by 368
PPARs: diverse regulators in energy metabolism and metabolic diseases
Wang, Y.-X. (2010) · Cell Research · doi:10.1038/cr.2010.13 · Cited by 366
The metabolic syndrome: role of skeletal muscle metabolism.
Stump, C. S., Henriksen, E. J., Wei, Y., & Sowers, J. R. (2006) · Annals of Medicine · doi:10.1080/07853890600888413 · Cited by 362
Berry, D. C., & Noy, N. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01742-08 · Cited by 345
“by on January 30, 2010 mcb.asm.org Downloaded from insulin sensitivity in obesity-prone mouse models, and enhances exercise endurance ( 3 , 6, 18, 26, 41, 42).”
BackgroundInfluentialNuclear receptors: Decoding metabolic disease
Sonoda, J., Pei, L., & Evans, R. M. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.016 · Cited by 313
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Proctor, G., Jiang, T., Iwahashi, M., Wang, Z., Li, J., & Levi, M. (2006) · Diabetes · doi:10.2337/db05-0603 · Cited by 303
In Vivo Correction of COX Deficiency by Activation of the AMPK/PGC-1α Axis
Viscomi, C., Bottani, E., Civiletto, G., Cerutti, R., Moggio, M., Fagiolari, G., Schon, E. A., Lamperti, C., & Zeviani, M. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.011 · Cited by 292
Miyashita, K., Itoh, H., Tsujimoto, H., Tamura, N., Fukunaga, Y., Sone, M., Yamahara, K., Taura, D., Inuzuka, M., Sonoyama, T., et al. (2009) · Diabetes · doi:10.2337/db09-0393 · Cited by 288
PPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
“Several abnormalities have been observed in mice lacking PPARβ/δ which include impaired wound healing, a decrease in adipose mass, and disturbed inflammatory reactions in skin [61].”
BackgroundA PPARγ–FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis
Jonker, J. W., Suh, J. M., Atkins, A. R., Ahmadian, M., Li, P., Whyte, J., He, M., Juguilon, H., Yin, Y.-Q., Phillips, C. T., et al. (2012) · Nature · doi:10.1038/nature10998 · Cited by 280
Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart
Burkart, E. M., Sambandam, N., Han, X., Gross, R. W., Courtois, M., Gierasch, C. M., Shoghi, K., Welch, M. J., & Kelly, D. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32578 · Cited by 279
Lipid metabolism and lipophagy in cancer
Maan, M., Peters, J. M., Dutta, M., & Patterson, A. D. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.097 · Cited by 275
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
Activity-Dependent Signaling Pathways Controlling Muscle Diversity and Plasticity
Schiaffino, S., Sandri, M., & Murgia, M. (2007) · Physiology · doi:10.1152/physiol.00009.2007 · Cited by 255
O'Sullivan, S. E., & Kendall, D. A. (2010) · Immunobiology · doi:10.1016/j.imbio.2009.09.007 · Cited by 247
Regulation of Bile Acid and Cholesterol Metabolism by PPARs
Li, T., & Chiang, J. Y. L. (2009) · PPAR Research · doi:10.1155/2009/501739 · Cited by 241
“Activation of PPARδ has been shown to prevent dyslipidemia and obesity in animal models of metabolic syndromes [5, 6].”
Eisele, N. A., Ruby, T., Jacobson, A., Manzanillo, P. S., Cox, J. S., Lam, L., Mukundan, L., Chawla, A., & Monack, D. M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.010 · Cited by 224
“Its combined activities make PPARδ a key regulator with the potential to therapeutically target multiple aspects of metabolic syndromes, including obesity and insulin resistance (Barish et al., 2006).”
BackgroundTachibana, K., Yamasaki, D., Ishimoto, K., & Doi, T. (2008) · PPAR Research · doi:10.1155/2008/102737 · Cited by 223
“PPARδ activators have been proposed for the treatment of metabolic disease and are under clinical trial [20, 21].”
MethodEhrenborg, E., & Krook, A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001560 · Cited by 213
“PPAR is ubiquitously expressed and acts as an important nutritional metabolic sensor and regulator (Barish et al., 2006).”
BackgroundPPARδ-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis
Takata, Y., Liu, J., Yin, F., Collins, A. R., Lyon, C. J., Lee, C.-H., Atkins, A. R., Downes, M., Barish, G. D., Evans, R. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708647105 · Cited by 210
Self-citationEcheverría, F., Ortiz, M., Valenzuela, R., & Videla, L. A. (2016) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2016.10.001 · Cited by 206
High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity
Mana, M. D., Hussey, A. M., Tzouanas, C. N., Imada, S., Barrera Millan, Y., Bahceci, D., Saiz, D. R., Webb, A. T., Lewis, C. A., Carmeliet, P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109212 · Cited by 204
“, 1993) and, upon ligand stimulation, which includes dietary fats or their derivatives, drive PPAR-specific transcriptional programs (Barish et al., 2006; Ordentlich et al., 2001).”
BackgroundJung, T. W., Lee, S. H., Kim, H.-C., Bang, J. S., Abd El-Aty, A. M., Hacımüftüoğlu, A., Shin, Y. K., & Jeong, J. H. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0147-5 · Cited by 203
Ziouzenkova, O., & Plutzky, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.081 · Cited by 203
Eichner, L. J., & Giguère, V. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.03.121 · Cited by 198
Nutritional management of the transition cow in the 21st century – a paradigm shift in thinking
Roche, J. R., Bell, A. W., Overton, T. R., & Loor, J. J. (2013) · Animal Production Science · doi:10.1071/an12293 · Cited by 197
PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis
Barish, G. D., Atkins, A. R., Downes, M., Olson, P., Chong, L.-W., Nelson, M., Zou, Y., Hwang, H., Kang, H., Curtiss, L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711875105 · Cited by 196
Self-citationPeroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Jay, M., & Ren, J. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802067 · Cited by 196
Between Death and Survival: Retinoic Acid in Regulation of Apoptosis
Noy, N. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155509 · Cited by 193
PPAR dual agonists: Are they opening Pandora's Box?
BALAKUMAR, P., ROSE, M., GANTI, S., KRISHAN, P., & SINGH, M. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.03.002 · Cited by 190
Gut microbiota mediates the anti-obesity effect of calorie restriction in mice
Wang, S., Huang, M., You, X., Zhao, J., Chen, L., Wang, L., Luo, Y., & Chen, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-31353-1 · Cited by 183
PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part I: PPAR-α
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2016-0059 · Cited by 183
Krämer, D. K., Al-Khalili, L., Guigas, B., Leng, Y., Garcia-Roves, P. M., & Krook, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702329200 · Cited by 180
Yessoufou, A., & Wahli, W. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13071 · Cited by 154
Redox regulation of mitochondrial biogenesis
Piantadosi, C. A., & Suliman, H. B. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.014 · Cited by 177
Mahmoud, A. M., Hussein, O. E., Hozayen, W. G., & El-Twab, S. M. A. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.04.009 · Cited by 176
Interference of pollutants with PPARs: endocrine disruption meets metabolism
Casals‐Casas, C., Feige, J. N., & Desvergne, B. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.207 · Cited by 174
The CD36-PPARγ Pathway in Metabolic Disorders
Maréchal, L., Laviolette, M., Rodrigue-Way, A., Sow, B., Brochu, M., Caron, V., & Tremblay, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051529 · Cited by 170
“PPARβ/δ is ubiquitously expressed and shares similar functions with PPARα in promoting FA oxidation in metabolic tissues such as skeletal muscle, liver and heart [10,11].”
BackgroundPPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed, W., Ziouzenkova, O., Brown, J., Devchand, P., Francis, S., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01825.x · Cited by 153
Mahmoud, A. M., Germoush, M. O., Alotaibi, M. F., & Hussein, O. E. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.047 · Cited by 169
Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies
Lee, S., Van Bergen, N. J., Kong, G. Y., Chrysostomou, V., Waugh, H. S., O’Neill, E. C., Crowston, J. G., & Trounce, I. A. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2010.07.015 · Cited by 169
Krentz, A. J., Clough, G., & Byrne, C. D. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00670.x · Cited by 168
Carotenoids and apocarotenoids in cellular signaling related to cancer: A review
Sharoni, Y., Linnewiel‐Hermoni, K., Khanin, M., Salman, H., Veprik, A., Danilenko, M., & Levy, J. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100311 · Cited by 168
Mahmoud, A. M., & Dera, H. S. A. (2015) · Genes & Nutrition · doi:10.1007/s12263-015-0491-1 · Cited by 167
“Upon ligand binding, they form heterodimers with retinoid X receptor (RXR) and result in modulation of gene transcription (Barish et al. 2006).”
BackgroundKarnieli, E., & Armoni, M. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90306.2008 · Cited by 139
Qin, X., Xie, X., Fan, Y., Tian, J., Guan, Y., Wang, X., Zhu, Y., & Wang, N. (2008) · Hepatology · doi:10.1002/hep.22334 · Cited by 148
“Our findings are as follows: (1) PPAR induces the expression of Insig-1, thus diminishing the proteolytic processing and, hence, suppressing the activity of SREBP-1, a crucial transcription factor controlling lipogenesis; (2) Insig-1 is a direct target of PPAR ; (3) PPAR inhibits the gene expression of the SREBP-1 tar…”
MethodRetinoic Acid Actions through Mammalian Nuclear Receptors
Huang, P., Chandra, V., & Rastinejad, F. (2014) · Chemical Reviews · doi:10.1021/cr400161b · Cited by 162
Oishi, Y., Manabe, I., Tobe, K., Ohsugi, M., Kubota, T., Fujiu, K., Maemura, K., Kubota, N., Kadowaki, T., & Nagai, R. (2008) · Nature Medicine · doi:10.1038/nm1756 · Cited by 160
“Because a growing body of evidence indicates that PPAR-δ is a key transcription factor governing fatty acid metabolism, PPAR-δ is now considered to be an attractive target for the development of therapeutic strategies against metabolic syndrom”
BackgroundNuclear receptors, mitochondria and lipid metabolism
Alaynick, W. A. (2008) · Mitochondrion · doi:10.1016/j.mito.2008.02.001 · Cited by 159
The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance
Plutzky, J. (2011) · Circulation Research · doi:10.1161/circresaha.110.226860 · Cited by 159
Peroxisome proliferator-activated receptors, Metabolic Syndrome and Cardiovascular Disease
Azhar, S. (2010) · Future Cardiology · doi:10.2217/fca.10.86 · Cited by 159
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157
Smad3 Deficiency in Mice Protects Against Insulin Resistance and Obesity Induced by a High-Fat Diet
Tan, C. K., Leuenberger, N., Tan, M. J., Yan, Y. W., Chen, Y., Kambadur, R., Wahli, W., & Tan, N. S. (2011) · Diabetes · doi:10.2337/db10-0801 · Cited by 146
Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)
Takada, I., & Makishima, M. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1703952 · Cited by 155
High-Fat Diet and Female Fertility
Hohos, N. M., & Skaznik-Wikiel, M. E. (2017) · Endocrinology · doi:10.1210/en.2017-00371 · Cited by 135
Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0111 · Cited by 153
Fuel economy in food‐deprived skeletal muscle: signaling pathways and regulatory mechanisms
de Lange, P., Moreno, M., Silvestri, E., Lombardi, A., Goglia, F., & Lanni, A. (2007) · The FASEB Journal · doi:10.1096/fj.07-8527rev · Cited by 136
Bastin, J., Aubey, F., Rötig, A., Munnich, A., & Djouadi, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1701 · Cited by 142
“Interestingly, chronic mice treatment with a PPAR agonist also resulted in the stimulation of OXPHOS gene expression in skeletal muscle, together with a global increase in oxidative metabolism (10, 11, 37).”
BackgroundMahmoud, A. M., Hussein, O. E., Hozayen, W. G., Bin-Jumah, M. N., & El-Twab, S. M. A. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-07532-6 · Cited by 152
Jung, T. W., Hwang, H.-J., Hong, H. C., Yoo, H. J., Baik, S. H., & Choi, K. M. (2015) · Diabetologia · doi:10.1007/s00125-015-3663-z · Cited by 145
Rodríguez-Calvo, R., Serrano, L., Coll, T., Moullan, N., Sánchez, R. M., Merlos, M., Palomer, X., Laguna, J. C., Michalik, L., Wahli, W., et al. (2008) · Diabetes · doi:10.2337/db08-0176 · Cited by 121
Bartolomucci, A., La Corte, G., Possenti, R., Locatelli, V., Rigamonti, A. E., Torsello, A., Bresciani, E., Bulgarelli, I., Rizzi, R., Pavone, F., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606102103 · Cited by 134
Bonnefont, J. P., Bastin, J., Laforêt, P., Aubey, F., Mogenet, A., Romano, S., Ricquier, D., Gobin-Limballe, S., Vassault, A., Behin, A., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.55 · Cited by 127
Does calorie restriction induce mitochondrial biogenesis? A reevaluation
Hancock, C. R., Han, D., Higashida, K., Kim, S. H., & Holloszy, J. O. (2011) · The FASEB Journal · doi:10.1096/fj.10-170415 · Cited by 131
Role and function of macrophages in the metabolic syndrome
Bhargava, P., & Lee, C.-H. (2012) · Biochemical Journal · doi:10.1042/bj20111708 · Cited by 114
AMPK-Dependent Metabolic Regulation by PPAR Agonists
Lee, W. H., & Kim, S. G. (2010) · PPAR Research · doi:10.1155/2010/549101 · Cited by 127
“Although PPARβ/δ is ubiquitously expressed in most tissues, high level of PPARβ/δ (NR1C2) is observed in skeletal muscle, suggesting that it is involved in energy metabolism [17].”
BackgroundNuclear receptors as therapeutic targets for Alzheimer's disease
Mandrekar-Colucci, S., & Landreth, G. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.594043 · Cited by 126
A Role of the Bile Salt Receptor FXR in Atherosclerosis
Hageman, J., Herrema, H., Groen, A. K., & Kuipers, F. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197897 · Cited by 119
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 112
“…PPAR/RXR heterodimer in turn binds to PPAR responsive regulatory elements in the promoter region of target genes (Willson et al. 2001; Ajjan and Grant 2008), including those involved in adipogenesis, lipid metabolism, inflammation, and the maintenance of metabolic homeostasis (Barish et al. 2006).”
BackgroundKruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation
Haldar, S. M., Jeyaraj, D., Anand, P., Zhu, H., Lu, Y., Prosdocimo, D. A., Eapen, B. L., Kawanami, D., Okutsu, M., Brotto, L. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121060109 · Cited by 125
“Conversely, the inability to adjust to changes in energy demand or nutrient supply can lead to organ dysfunction and disease (1, 7).”
BackgroundPPARβ/δ governs Wnt signaling and bone turnover
Scholtysek, C., Katzenbeisser, J., Fu, H., Uderhardt, S., Ipseiz, N., Stoll, C., Zaiss, M. M., Stock, M., Donhauser, L., Böhm, C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3146 · Cited by 124
Jia, Y., Kim, J., Jun, H., Kim, S., Lee, J., Hoang, M. H., Hwang, K.-Y., Um, S., Chang, H. I., & Lee, S. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100798 · Cited by 124
CRY1/2 Selectively Repress PPARδ and Limit Exercise Capacity
Jordan, S. D., Kriebs, A., Vaughan, M., Duglan, D., Fan, W., Henriksson, E., Huber, A.-L., Papp, S. J., Nguyen, M., Afetian, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.002 · Cited by 111
He, H., Yang, D., Ma, L., Luo, Z., Ma, S., Feng, X., Cao, T., Yan, Z., Liu, D., Tepel, M., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.143958 · Cited by 121
Nuclear Receptors in Bone Physiology and Diseases
Imai, Y., Youn, M.-Y., Inoue, K., Takada, I., Kouzmenko, A., & Kato, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2012 · Cited by 88
Chen, Y., Sheu, M., Tsai, K., Yang, R., & Liu, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066611 · Cited by 119
Retracted
Metadata
- Authors
- Barish, G. D.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Barish, G. D.
- ORCID
- Barish, G. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-01
- Volume
- 116
- Issue
- 3
- Pages
- 590-597
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1386117
- OpenAlex
- W1987601141
- Cited by
- 641
- References
- 100
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 29 · 2014: 31 · 2013: 39 · 2012: 46
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- March of Dimes Foundation
- Larry L. Hillblom Foundation
- National Institutes of Health (U19DK62434)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (P50HL56989, P50HL056989)
- National Institute of Diabetes and Digestive and Kidney Diseases (U19 DK-62434, U19DK062434, F32DK071478)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- PPARδ, PPARα, PPARγ, metabolic syndrome, insulin resistance, hypertriglyceridemia, obesity, fatty acid degradation, adipose tissue, skeletal muscle, macrophage inflammation, atherosclerosis, nuclear receptors, weight gain, physical endurance
- MeSH terms
- Animals, Humans, Myocardium, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.